Q1 2023 Results

Company overview Financial review Innovation: Pipeline overview Financial performance Cardiovascular Immunology Conclusions Appendix Innovation: Clinical trials Neuroscience Oncology MIJ821 - NR2B negative allosteric modulator (NAM) NCT04722666 (CMIJ821A12201) Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Major depressiv disorder with acute suicidal ideation or behavior Phase 2 195 Change from baseline to 24 hours in the total score of the Montgomery Asberg Depression Rating Scale (MADRS) MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29 Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29 MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 followed by Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29 MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1 followed by Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 15 and Day 29 Participants who have suicidal ideation with intent Readout Milestone(s) 2023 (interim) Publication TBD 65 Investor Relations | Q1 2023 Results References Abbreviations Other NOVARTIS | Reimagining Medicine

View entire presentation